643 related articles for article (PubMed ID: 16474853)
21. Sorafenib: delivering a targeted drug to the right targets.
Flaherty KT
Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib (BAY 43-9006): review of clinical development.
Ng R; Chen EX
Curr Clin Pharmacol; 2006 Sep; 1(3):223-8. PubMed ID: 18666747
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
25. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.
Wilhelm S; Carter C; Lynch M; Lowinger T; Dumas J; Smith RA; Schwartz B; Simantov R; Kelley S
Nat Rev Drug Discov; 2006 Oct; 5(10):835-44. PubMed ID: 17016424
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib for the treatment of advanced renal cell carcinoma.
Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
[TBL] [Abstract][Full Text] [Related]
27. Selection of patients with hepatocellular carcinoma for sorafenib.
Abou-Alfa GK
J Natl Compr Canc Netw; 2009 Apr; 7(4):397-403. PubMed ID: 19406040
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib in renal cell carcinoma.
Flaherty KT
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):747s-752s. PubMed ID: 17255304
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI
Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321
[TBL] [Abstract][Full Text] [Related]
30. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
Kim R; Byrne MT; Tan A; Aucejo F
Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib: in hepatocellular carcinoma.
Simpson D; Keating GM
Drugs; 2008; 68(2):251-8. PubMed ID: 18197728
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
Chang YS; Adnane J; Trail PA; Levy J; Henderson A; Xue D; Bortolon E; Ichetovkin M; Chen C; McNabola A; Wilkie D; Carter CA; Taylor IC; Lynch M; Wilhelm S
Cancer Chemother Pharmacol; 2007 Apr; 59(5):561-74. PubMed ID: 17160391
[TBL] [Abstract][Full Text] [Related]
33. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
[TBL] [Abstract][Full Text] [Related]
34. An update on the medical therapy of advanced metastatic renal cell carcinoma.
Kruck S; Merseburger AS; Gakis G; Kramer MW; Stenzl A; Kuczyk MA
Scand J Urol Nephrol; 2008; 42(6):501-6. PubMed ID: 18615363
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib in advanced clear-cell renal-cell carcinoma.
Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Siebels M; Negrier S; Chevreau C; Solska E; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Freeman S; Schwartz B; Shan M; Simantov R; Bukowski RM;
N Engl J Med; 2007 Jan; 356(2):125-34. PubMed ID: 17215530
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma.
Reddy GK; Bukowski RM
Clin Genitourin Cancer; 2006 Mar; 4(4):246-8. PubMed ID: 16729906
[TBL] [Abstract][Full Text] [Related]
38. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.
Guan YS; He Q
Expert Opin Pharmacother; 2011 Feb; 12(2):303-13. PubMed ID: 21226640
[TBL] [Abstract][Full Text] [Related]
40. Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report.
Castagneto B; Stevani I; Giorcelli L; Montefiore F; Bigatti GL; Pisacco P; Cosimi MF
Med Oncol; 2011 Dec; 28(4):1384-8. PubMed ID: 20552299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
